TITLE

Antiviral Briefs

PUB. DATE
October 2000
SOURCE
AIDS Patient Care & STDs;Oct2000, Vol. 14 Issue 10, p567
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents various medical news briefs related to side effects of antiviral drugs for HIV infections. Ability of protease inhibitors to cause sexual dysfunction; Role of highly active antiretroviral therapy in causing curly hair; Interaction between Viagra and ritonavir or saquinavir.
ACCESSION #
3760480

 

Related Articles

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine. Glick, Roy M.; Mellors, John W. // Annals of Internal Medicine;07/04/2000, Vol. 133 Issue 1, p35 

    Describes the three-year follow-up of patients randomly assigned to receive indinavir, zidovudine and lamivudine in an ongoing clinical trial. Test of the durability of the suppression of viremia in HIV-infected patients through antiretroviral regimens containing HIV protease inhibitors;...

  • Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients. Benson, Constance A.; Deeks, Steven G.; Brun, Scott C.; Gulick, Roy M.; Eron, Joseph J.; Kessler, Harold A.; Murphy, Robert L.; Hicks, Charles; King, Martin; Wheeler, David; Feinberg, Judith; Stryker, Richard; Sax, Paul E.; Riddler, Sharon; Thompson, Melanie; Real, Kathryn; Hsu, Ann; Kempf, Dale; Japour, Anthony J. // Journal of Infectious Diseases;3/1/2002, Vol. 185 Issue 5, p599 

    The safety and antiviral activity of lopinavir (Lpv), a protease inhibitor (PI) coformulated with ritonavir (Rtv) to enhance its pharmacokinetic properties, were evaluated in 70 patients with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels of 1000-100,000 copies/ mL on a first...

  • Marked Elevation of the Creatine Phosphokinase Level in a Patient Receiving Tenofovir. Shere-Wolfe, K.D.; Verley, J.R. // Clinical Infectious Diseases;11/1/2002, Vol. 35 Issue 9, p3 

    Examines the elevation of the creatine phosphokinase (CPK) level in the patients receiving tenofovir for the treatment of HIV. Addition of tenofovir to a stable regimen; Comparison of the elevation in the CPK level with the limit of it; Possibility for the interaction between tenofovir and...

  • EFAVIRENZ POTENT IN ADULTS.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p170 

    Cites the findings of a DuPont 006 study regarding the use of efavirenz when compared to the protease inhibitor indinavir. Support for the use of efavirenz among HIV patients who are treatment-naive; Random assignments into possible treatment regimens.

  • Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence. Max, Blake; Sherer, Renslow // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS96 

    Examines the therapeutic agents included in the highly active antiretroviral therapy (HAART) for the treatment of patients with HIV infections. Link between poor adherence and failure of antiretroviral therapy; Threat of short term-adverse effects to successful introduction and maintenance of...

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

  • Gynaecomastia associated with saquinavir therapy. Donovan, Basil; Bodsworth, Neil J.; Mulhall, Brian P.; Allen, Debbie; Donovan, B; Bodsworth, N J; Mulhall, B P; Allen, D // International Journal of STD & AIDS;Jan1999, Vol. 10 Issue 1, p49 

    Gynaecomastia has been reported in an HIV-1- infected man treated with a triple antiviral regimen including indinavir1. We describe 4 cases of men with gynaecomastia associated with saquinavir (hard gel capsule) therapy who denied taking any hormonal supplements or opiates.

  • A Risk-Benefit Assessment of HIV Protease Inhibitors. Moyle, G.J.; Gazzard, B.G. // Drug Safety;Apr1999, Vol. 20 Issue 4, p299 

    The use of triple therapy regimens, often called highly active antiretroviral therapy (HAART), generally involving 2 nucleoside analogues and an HIV protease inhibitor, have been endorsed as the standard of care for persons with HIV initiating therapy by a number of sets of international...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics